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Abstract
Paclitaxel is a microtubule stabilizing drug that causes dividing cells to arrest and then undergo apoptosis. It also has anti-
angiogenic activity because it alters cytoskeletal structure, affecting migration and invasion. Paclitaxel is an effective
treatment for AIDS-related Kaposi’s sarcoma (KS). KS is a tumor in which there is marked proliferation of endothelial cells
in addition to the tumor cells, which themselves share many markers with activated (proliferating) endothelial cells. We
sought to determine the mechanism by which paclitaxel exerts its anti-KS tumor effects. In vitro, KS cells are very sensitive
to paclitaxel, with half-maximal growth inhibition observed at 0.8 nM. Inhibition of migration of KS cells was also observed
at nanomolar concentrations of the drug. Paclitaxel induced cell cycle arrest with an accumulation of cells in sub-G1.This
was accompanied in vitro by various events typical of apoptosis: phosphorylation of two anti-apoptotic proteins Bcl-2 and
Bcl-xL, release of cytochrome c into the cytoplasm, cleavage and activation of caspase-3. In vitro results were borne out by
studies of KS tumor xenografts in nude mice. Paclitaxel (10 mg/kg) inhibited tumor growth by 75% over 21 days.
Histological examination of the tumors revealed a decrease in proliferative index,a decrease in the number of mitotic figures
and an increase in apoptotic cells compared to tumors from untreated mice.
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Introduction
Kaposi’s sarcoma is the most common tumor in
patients with human immunode® ciency virus type
1 (HIV-1) infection.
1 Clinically, KS manifests most
commonly on the skin and mucus membranes as
multicentric lesions, with subsequent spread to
visceral organs.
1 KS-related mortality is secondary
to visceral organ disease.There has been debate as
to whether KS is a true neoplasm, or merely
represents a local hyperproliferation reaction in
response to in¯ ammatory cytokines and growth
factors. With the results of two groups that show
clonality in KS lesions this debate appears to be
resolving in favor of the neoplastic nature of the
disease.
2,3
KSHV/HHV-8, a recently identi® ed herpes virus,
is a strong candidate for the etiologic agent for all
forms of KS, whether classical, AIDS-associated or
endemic.Molecularepidemiologystudieshave shown
that nearly all KS tumors contain viral genome,
suggesting an etiological link to this virus.
4 Sero-
epidemiology studies show that KS patients have a
very high prevalence of KSHV/HHV8 antibodies
(90%) which is elevated above the non-KS popula-
tion (5± 20% in the USA). Further, in countries with
HIV but no documented KS, KSHV seroprevalence
is very low (2± 4%).
5
Pathologically, the tumor exhibits an extensive
vascular network of slit-like spaces, which differ from
normal vessels in that they lack basementmembranes
and the presence of abnormal spindle-shaped
endothelial cells (tumor cells) lining these vessels.
The pathological examination of the tumors suggests
that the origin of KS tumor cells is endothelial, a
hypothesis that is supported by phenotypic studies.
Markers shared with endothelial cells include lectin
bindingsites for Ulex europeaus agglutinin-1(UEA-1),
CD34, EN-4, PAL-E,
6ELAM-1,
7VE-cadherin
8and
the recently identi® ed endothelial cell speci® c tyro-
sine kinase receptors, VEGFR-1 (Flt-1), VEGFR-2
(Flk-1/KDR),VEGFR-3 (Flt-4),Tie-1 and Tie-2.
9± 11
In addition to expressing many endothelial proteins,
KS cell growth is strongly dependent on the
angiogenic factors vascular endothelial growth factor
(VEGF),
9 basic ® broblast growth factor (bFGF),
12
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P.S.G., unpublished data).
Paclitaxel has shown potent anti-tumor activity in
several tumor types.
13± 16 Paclitaxel increases tubulin
polymerization, which results in cell-cycle arrest due
to inhibitionof mitotic spindleformation.
17Prolonged
cell-cycle arrest has been associated with phosphor-
ylation of the Bcl-2 protein.
18 The Bcl-2 family of
proteinsplays a central role in programmedcell death
or apoptosis, in which anti-apoptotic members such
as Bcl-2 and Bcl-xL balance the activities of the
pro-apoptotic members such as Bax and Bad.
19,20
Heterodimerization of Bcl-2 with Bax is critical in
preventing Bax-mediated apoptosis.
21,22 Bcl-2 and
Bax have additional opposing actions in apoptosis
sinceBcl-2 preventsthe releaseof cytochrome c from
mitochondria
23 while Bax promotes cytochrome c
release.
24 Cytochrome c release results in binding to
Apaf-1 followedby activation of caspase 9 and effector
caspases
25 that are active in the effector phase of
apoptosis.
26
In addition to inducing apoptosis, paclitaxel may
also exert its anti-tumor activity through inhibition of
angiogenesis.Paclitaxel alters cytoskeletal structures
and inhibits endothelial cell migration in vitro and in
vivo.
27Paclitaxel has also been shown to inhibitangio-
genesis in the chicken chorio-allantoic membrane
(CAM) assay
28 and bFGF induced angiogenesis in
the mouse corneal neovascularization model.
29
Since KS is a highly vascular tumor we ® rst sought
to determine the sensitivity of KS to paclitaxel in
vitro and in vivo.We found that very low (nanomole)
concentrationsof paclitaxel inducedtumor cell death.
We show that the mechanism of anti-tumor action of
paclitaxel in KS is accompanied by phosphorylation
of Bcl-2, release of cytochrome c into the cytoplasm
and activation of caspase-3.
Materials and methods
Cell proliferation assays
The immortalized KS cell lines KS Y-1
30 and
KS-SLK
31 were grown in wells coated with 1.5%
gelatin in KS mediumconsistingof RPMI-1640 (Life
Technologies, Gaithersburg, MD), 100 U/ml
penicillin,100 m g/ml streptomycin,2 mM glutamine,
1% essentialand non-essentialamino acids,10% fetal
bovine serum (FBS: Life Technologies), and 1%
Nutridoma-HU (Boehringer Mannheim, Indiana-
polis, IN). HUVEC (Clonetics,San Diego,CA) were
grown in mediumcontainingepidermalgrowth factor
and according to the instructions of the supplier.
Cells were plated at a density of 10 000 cells/well in
48-well gelatin coated plates on day 0. Similarly,
AoSM (Clonetics, San Diego) cells were seeded in
48 well plates at the same density in their growth
media on day 0. On days 1 and 3 cells were treated
with various concentration of paclitaxel. On day 5,
cells were treated with 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) at a ® nal
concentration of 0.5 mg/ml.Cells were incubated for
2 hours, medium was aspirated and the cells were
dissolved in acidic isopropanol (90% isopropanol,
0.5% SDS and 40 mM HCl). Developed color was
read in an ELISA reader using the isopropanol as
blank (Molecular Devices, CA).
Cell migration assays
Cell migration assays were performed in transwells
with 8 m m pores (Costar, Cambridge, MA). Brie¯ y,
wells were coated with ® bronectin (25 m g/ml)
overnight, and the endothelial cells or KS cells were
plated in 100 m l of DMEM/0.4% FCS in the upper
chamber. 500 m l of DMEM/0.4% FCS was added to
the lower chamber and incubated at 37Ê C for 1 hour.
Paclitaxel (0.01± 100 nM) was added to the upper
chamber, and chemotaxis agents (VEGF 20 ng/ml)
to the lower chamber.The plates were incubated for
16 hours at 37Ê C and the cells crossing the
® bronectin-plated membrane were quantitated after
wiping the cells off the upper chamber with a cotton
swab. The cells across the membrane were stained
with Diff-Quik stain set according to the
manufacturer’s instruction (Dade Diagnostics Inc.,
Aguada,PR).The cells were counted at 320 X in four
randomly selected ® elds.The experiments were done
in duplicate and repeated at least three times.
Apoptosis assays
Internuclear fragmentation of genomic DNA was
assessed after incubation of the cells with paclitaxel.
DNA from 1m10
6 cells was extracted and size-
fractionated by agarose gel electrophoresis as
described previously.
32 KS cells were also analyzed
by ¯ ow cytometry for cell cycle and apoptosis after
incubation with paclitaxel.The cell pellets were ® xed
in 70% alcohol, washed and the nuclei were stained
with propidium iodide solution for analysis as
described previously.
33The samples were read on a
Coulter Elite ¯ ow cytometer using Elite software
program 4.0 for two-color detection.The percentage
of cells in the apoptotic sub-G1, G1, S, and G2-M
phase were calculated using Multicycle software
(Phoenix Flow Systems, San Diego, CA).
Protein analysis
The levels of Bcl-xL, Bcl-2 and Bax and their phos-
phorylation status, levels of cytosolic cytochrome c,
activation of caspase-3, proteolysis of poly (ADP-
ribose) polymerase (PARP), and cleavage product of
DNA fragment factor (DFF) in control cells and in
response to paclitaxel treatment were also examined
in KS cells.These assays were performed byWestern
blot using speci® c antibodies conjugated to
horseradish peroxidase.
34± 38
38 J.Cai et al.In vivo tumor growth
In vivo studies were performed in BALB/c NU
+/nu
+
athymic mice by implanting KS Y-1 cells (10 million
cellseach)subcutaneously.Miceweretreatedwithpacli-
taxel (5 and 10 mg/kg) or an equal amount of vehicle
control intraperitoneally on days 1, 5, 9, 14 and 21.
Tumor sizes were measuredon days 14 and 21.Tumor
volume was calculated with the formula V = 0.52LW
2.
Sixmiceweretreated in eachgroup.Micewerehandled
throughout in compliance with IACUC regulations.
Histological analysis of in vivo tumors
In other experiments, tumors were allowed to grow
for 14 days and treated with 5, 10, or 20 mg/kg of
paclitaxel.Tumors were excised 24 hours later, ® xed
in 4% paraformaldehyde, imbedded in paraffin,
sectioned and analyzed for the mitotic index, and
apoptosis in situ. Immunoperoxidase staining for the
proliferation-related antigen, Ki-67 was performed
using MIB-1 monoclonal antibody (Immunotech,
Marseilles,France).After incubationwith the primary
antibody, staining was completed using the ABC
immunoperoxidasemethod on an automated stainer
(Techmate 1000, BioTek,Santa Barbara,CA).Diami-
nobenzidine (DAB) was used as the peroxidase
substrate. TUNEL staining for apoptosis was
performed usingthe ApopTag in situ apoptosis detec-
tion kit (Oncor,Gaithersburg, MD) according to the
protocolsuppliedby the manufacturer.In this method
cut DNA is localized in situ by end-labeling, using
terminaldeoxyribonucleotidyltransferase (TdT) and
an digoxigenin-deoxyuridine5-triphosphate substrate.
The bound digoxigenin is detected immunohisto-
chemically using antidigoxigenin± peroxidase
antibodies. Peroxidase was visualized using
aminoethylcarbizole (AEC) as the chromogen (AEC
kit, Zymed Lab Inc., San Francisco, CA). Negative
controls included substitution of water for TdT. For
each tumor, cell density was determined on H&E
sections by counting the number of nuclei in 5
representative 1 mm
2 sections. The number of
morphologically identi® able mitotic ® gures was
counted in these same regions of the H&E stained
sections.The labeling index for MIB-1 and TUNEL
positive cells was performed by determining the
percentageof labeled nucleiin 5 representative1 mm
2
sections from each tumor.
Results
Paclitaxel inhibits KS cell proliferation and migration
We examined the effects of paclitaxel on KS cell
proliferation in vitro.The 50% inhibitory concentra-
tion (IC50) for paclitaxel was 0.8 nM,and 90% inhibi-
tion was observed at 10 nM (Fig. 1a). In contrast,
endothelialcells(HUVEC) and aortic smooth muscle
cells (AoSM),were less sensitive,with IC50of 6.6 nM
and 4.7 nM, respectively. We also investigated the
effects of paclitaxel on KS cell migration in response
to bFGF. Paclitaxel inhibited KS cell migration with
an IC50 of 1.1 nM (Fig. 1b). Inhibition of migration
(16 hours) occurred earlier than inhibition of
proliferation (5 days). For all concentrationsof pacli-
taxel except the highest tested (100 nM), we do not
observe cell death at 16 hours.
Paclitaxel induces apoptosis in KS cells
Exposure of KS cells to paclitaxel produced a dose-
dependent increase in internucleosomal DNA
fragmentation (Fig. 2a).This was associated with an
increase in the fraction of sub-G1 cells with DNA
content below that of the interphase resting cells
(<2N) (Fig. 2b).AnnexinV is translocated to the cell
Figure 1. Taxol inhibits proliferation and migration of KS cells.(a) KSY-1, HUVEC and AoSM cells were plated at equal density
(1m10
3 cells/well) and treated with Taxol on days 1 and 3 at the concentrations shown. Cells were counted on day 5. (b) migration
assays were done in double chamber wells separated by a ® bronectin-coated membrane. Chemotaxis was induced by additionVEGF
(20 ng/ml) to the lower chamber.Cells (5m10
4/ml) were placed in the upper chamber in the presence and absence of paclitaxel at the
concentration shown.Migration of KSY-1 cells across the membrane was quantitated after overnight incubation.The results represent
the mean ±standard error of assays performed in quadruplicate.
Paclitaxel in Kaposi’s sarcoma 39surface during apoptosis and is used as a marker of
apoptotic cells.We stained KS cells exposed to 0.1 to
100 nM paclitaxel with Annexin V to determine the
fraction of apoptotic cells in vitro. It can be seen in
Fig. 3 that 25% of cells were apoptotic following 24
hourexposureto 100 nM paclitaxel.At500 nMpacli-
taxel, the highest concentration used in other experi-
ments reported in this study, 48% of cells exhibited
morphologic features of apoptosis.
Caspase-3 is activated upon paclitaxel treatment of
KS cells
We further investigated the mechanism of KS cell
death in response to paclitaxel. One of the pivotal
proteases active in apoptosis is caspase-3, which
degrades several protein substrates including poly
(ADP-ribose) polymerase (PARP).
37,38 Twenty-four
hour treatment of KS cells with paclitaxel resulted in
a dose-dependentcleavage of full-lengthprocaspase-3
(Fig.4a).This was associated with the degradation of
caspase-3 substrate PARP into its 85 kD (Fig. 4a)
and 31 kD (not shown) fragments.
Paclitaxel induces phosphorylation of Bcl-2 and Bcl-xL
in KS cells
The mechanism of paclitaxel-induced apoptosis
involves modulation of regulatory proteins such as
Bcl-2, Bcl-xL, and Bax. Figure 4b demonstrates that
exposure of KS cells to paclitaxel for 24 hours results
in the appearance of slower-mobility species
characteristic of the phosphorylated forms of Bcl-2
and Bcl-xL. Under the same treatment Bax levels were
unchanged. A time course of KS cell exposure to
500 nMpaclitaxelshowedthatphosphorylationof Bcl-2
and Bcl-xL had reached a peak by 5 hours, whereas
caspase-3 activation measured by cleavage of PARP
was not appreciable until 12 hours (Fig. 4c).
Cytochrome c is released by paclitaxel treatment in KS
cells
Release of cytochrome c from the mitochondria into
the cytosol may precede apoptosis. We determined
whether this occurredin KS cellsin responseto pacli-
taxel. Paclitaxel, but not etoposide, resulted in cyto-
chrome c release into the cytoplasm after 24 hour
treatment (Fig. 5).This release of cytochrome c was
associated with the induction of downstream apop-
totic events in the same cells. Two substrates of
caspase-3, PARP and DFF, were cleaved into smaller
forms (Fig. 5).
Figure 2. Taxol induces internucleosomal DNA fragmentation
and increasesthe fraction of sub-G1 cells with <2N DNA content.
(a) Following exposure of KSY-1 cells to 50 or 500 nMTaxol for
24 hours, the genomic DNA was extracted,puri® ed and subjected
to agarose gel electrophoresis.(b) Flow cytometric determination of
DNA content and cell cycle status of KSY-1 cells treated with
Taxol for 24 hours compared with untreated cells (control). The
areasof the plots that represent cells in sub-G1 and G2/M phaseof
the cell cycle are indicated.There is a dose-dependent increase in
sub-G1 cells with <2N DNA content.
Figure 3. Taxol treatment leads to apoptosis of KS cells.
Following exposure of the Kaposi’s sarcoma cell line, KSY-1, to
paclitaxel (0.1,1,10,and 100 nmol) for 24 hours,the cells were
trypsinized and stained for annexinV . Cells displaying annexin
V on the cell surface were quantitated by ¯ ow cytometry.
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The effects of paclitaxel on KS tumors in vivo were
nextdeterminedusingtumorxenograftsin nudemice.
Tumor response was observed in mice treated with a
paclitaxel dose of 10 mg/kg (Fig. 6a). In other
experiments, tumors were excised 24 hours after a
single dose of either 5 or 10 mg/kg and studied for
apoptosis in situ, and for their effect on the mitotic
index. A dose-dependent increase in the cells
undergoingapoptosis (Fig. 6b) and a decrease in the
mitotic index were observed (Fig. 6c). Comparison
of the histology of the control and paclitaxel treated
tumorsrevealed frequentmitotic ® guresin the control
tumors (Fig.6d) which were reducedupon paclitaxel
treatment (Fig. 6e). Immunoperoxidase staining for
the proliferation marker Ki-67 showed a signi® cant
reduction in paclitaxel treated compared to control
tumor (Figs 6g, f). TUNEL staining was performed
to quantify the in vivo apoptosis.When compared to
control (Fig. 6h) paclitaxel treated tumor (Fig. 6i)
showed a marked increase in the numberof TUNEL-
positive cells. When adjusted for cell density, the
increase in apoptosis was even more prominent.
Discussion
Paclitaxel has proven effective in the treatment of a
variety of cancers
13± 15 including Phase II trials in
Kaposi’s sarcoma.
16,39 Because of its highly vascular
Figure 4. Taxol induces Bcl-2 phosphorylation and the
molecular cascade of apoptosis in KS Y-1 cells. KS Y-1 cells
were exposed to the indicated concentration of Taxol for 24
hours.Western blot analysis of several apoptotic markers. (a)
Decrease in procaspase-3 (p32 caspase-3; by cleavage; see
text) and degradation of caspase-3 substrate 116 kD PARP
into its 85 kD and 31 kD (not shown) fragments. (b) Treat-
ment withTaxol produced a dose-dependent increase in slower
mobility phosphorylated Bcl-2 and Bcl-xL bands, whereas
Bax levels remain unaltered. (c)Western analyses of the levels
of p29Bcl-xL, p26Bcl-2, full-length caspase-3, as well as the
analysis of the caspase-3 activity by determining the in vitro
cleavage of
35S-labeled PARP by cellular protein extracts from
untreated and paclitaxel (500 nM) treated cells for 5, 8, 12,
and 24 hours. Exposure to 500 nM paclitaxel for ‡ 5 hours
resulted in a time-dependent increase in the phosphorylation
of Bcl-2 and Bcl-xL.A decline in the p32 caspase-3 levels and
PARP cleavage activity occurred after exposure to paclitaxel
for at least 12 hours.
Figure 5. Taxol induces apoptosis in KSY-1 cells by release of
cytochrome c.Western analysis of cytosolic cytochrome c (cyt c)
levels and the 45 kD subunit of DNA fragmentation factor
(DFF).
35S-labeled in vitro translated Poly (ADP-ribose)
polymerase (PARP) or its 85 and 31 kD cleavage products were
analyzed from the S-100 fraction from the untreated, etoposide-
treated (50 mmol for 4 hours), or paclitaxel-treated (50 mmol for
24 hours) KSY-1 cells.Treatment with paclitaxel but not etopo-
side induced cytosolic accumulation of cytochrome c as well as
PARP and DFF-45 cleavage activity.
Paclitaxel in Kaposi’s sarcoma 41Figure 6. Activity of paclitaxel on Kaposi’s sarcoma tumor growth in mice. (a) Mice were treated either with paclitaxel or
the control (6 mice per group) intraperitoneally (20 mg/kg) on days 1, 5, 9, 14 and 21.Tumors were measured on days 14 and
21.The results represent the mean ± standard error of tumor size. In other experiments, immunode® cient mice were injected with
10 million cells per mouse subcutaneously. Mice were treated with a single dose of paclitaxel at 5 or 10 mg intraperitoneally and
the tumors were excised after 24 hours and examined for (b) apoptosis in situ and (c) mitotic index. Histology of taxol-treated
tumors. H&E stained sections of control tumors (d) showed a cellular malignant tumor with frequent mitotic ® gures
(horizontal arrow heads). (e) Taxol-treated tumors showed fewer mitotic ® gures (horizontal arrow heads) and scattered apop-
totic bodies (horizontal arrows). (f) Immunoperoxidase staining for the proliferation related antigen Ki-67 using MIB-1
revealed a high labeling index in control tumors. (g) In taxol-treated tumors, the MIB-1 labeling index was signi® cantly lower.(h)
TUNEL staining for apoptotic cells revealed rare apoptotic cells (arrow heads) in control tumors. (i) Apoptotic cells were
signi® cantly more frequent in taxol treated cells (arrow heads).An H&E stained section of a typical KS lesion in an AIDS-KS
patient is shown (j).The area that is magni® ed in (k) is indicated by the white rectangle. (k) High power view of KS biopsy for
comparison to KSY-1 tumor xenograft in mice shown in panels D-I. Both the KSY-1 xenograft (d) and KS biopsy (k) show
similar tumor cells (vertical arrowheads in both panels) and the occurrence of slit-like spaces typical of KS lesions (vertical arrows
in both panels).
42 J.Cai et al.nature we hypothesized that KS would be especially
sensitive to paclitaxel, since both the apoptotic and
anti-angiogenic properties of the drug would be in
action against this tumor. We therefore set out to
examine the response of KS cells in vitro and in vivo
to paclitaxel.
KS cells were very sensitive to the cytotoxic effects
of paclitaxel in vitro. The concentration of half-
maximal growth inhibition (0.8 nM) was an order of
magnitudelowerthan reportedforseveralother tumor
cell types.
40± 42The cytotoxic activity of paclitaxel in
KS cells was due to apoptosis,and these effects could
be seen at a dose as low as 0.1 nM in vitro. Two
events indicative of apoptosis, characteristic DNA
banding resulting from internucleosomal cleavage,
and the appearance of annexinV on the outer surface
of the cell membranewere both observed upon pacli-
taxel treatment of KS cells.
Having established that paclitaxel induces apop-
tosis in KS cells, we next undertook to examine the
behavior of some of the important apoptotic
molecules in these cells. We showed that two anti-
apoptotic proteins, Bcl-2 and Bcl-xL, were expressed
in KS cells and phosphorylated after 24 hour treat-
ment with paclitaxel. Phosphorylation of Bcl-2 has
been regarded as a marker of apoptosis; however,
recent results suggest that phosphorylated Bcl-2 is
not in itself an apoptotic protein.
18,43Bcl-2 phospho-
rylation occurs in tandem with mitosis as a normal
part of the cell cycle and does not necessarily lead to
apoptosis. Bcl-2 can be considered a cell cycle
checkpoint protein that responds to mitotic spindle
defectsin analogy to the checkpointproteinp53 which
responds to DNA damage. It is interesting that KS
cells also express Bcl-xL, which can compensate for
Bcl-2 activity.
38 We noted that the levels of the
pro-apoptotic protein Bax did not change in response
to paclitaxel treatment. Presumably, the extended
phosphorylation of both Bcl-2 and Bcl-xL in this
system releases Bax from heterodimers with these
molecules to exert its downstream apoptotic effects.
Two of these documented effects are release of cyto-
chromec into the cytosol and activation of the caspase
family of proteases. We demonstrated that cyto-
chromec was released at the concentrationsthat were
used in the other in vitro assays.This is in agreement
with results that demonstrate that Bcl-2 blocks the
release of cytochrome c from the mitochondria and
that Bax enables its release.
23,24 In turn cytosolic
cytochrome c binds Apaf-1, activates caspase 9 and
leads to activation of the caspases, including caspase
3, which are the effectors of apoptosis.
25,26We thus
showed activation of caspase 3 by cleavage of its pro
form. In addition to showing that caspase-3 itself was
cleaved weshowedthat it was indeedactivated.Activa-
tion of caspase 3 coincided with the cleavage of
caspase 3 substrates, poly (ADP-ribose) polymerase
(PARP) and DNA fragmentation factor (DFF). In
this KS cell system peak levels of phosphorylation of
Bcl-2 and Bcl-xLpreceded peak caspase-3 activity by
at least 7 hours.This is in keeping with the current
paradigm of apoptosis in which Bcl-2 phosphoryla-
tion leads to free Bax, which in turn leads to release
of cytochrome c from the mitochondria, which then
initiates the ® nal phase of apoptosis where proteases
are released to effect cell death.
23± 26
The in vivo results in KS tumor xenografts in nude
mice mirror the in vitro results.There was signi® cant
(75%) reduction of tumor size in paclitaxel treated
mice and histology of the tumors revealed a decrease
in proliferation, a decrease in mitosis and extensive
apoptosis of tumor cells compared to untreated
controls. The major mechanism of paclitaxel anti-
tumor activity in this model appears to be induction
of apoptosis in the tumor cells.While we did show
that in vitro paclitaxel inhibited KS cell migration,
the contribution of anti-angiogenic effects of paclit-
axel was not investigated in vivo. However, there is
precedent for a multifaceted anti-angiogenic activity
of paclitaxel. Not only does paclitaxel inhibit angio-
genesis by interfering with migration of endothelial
cells,
27 but also it induces macrophage production of
the anti-angiogenic cytokine IL-12.
43This last point
may be of signi® cance in KS, which is a tumor highly
in® ltrated with macrophages.
In conclusion, the anti-KS effect of paclitaxel can
in large part be attributed to the apoptosis initiating
activity of the drug;however, there is a componentof
anti-angiogenic action since we showed that KS cell
migration was inhibitedat low concentrationsof pacli-
taxel.
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